Press Releases

Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica

11/20/20

Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo

10/13/20

Auris Medical Provides Business Update and Reports First Half 2020 Financial Results

09/17/20

Auris Medical to Report First Half 2020 Financial Results and Provide Business Update on Thursday, September 17, 2020

09/11/20

Auris Medical Launches Development of Drug-Free Nasal Spray for Protection against Airborne Pathogens and Allergens

09/08/20

Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo

09/03/20

Auris Medical Regains Listing Compliance with NASDAQ Minimum Bid Requirement

08/20/20

Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo

07/29/20

Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study

05/26/20

Auris Medical Provides Business Update and Reports Second Half and Full Year 2019 Financial Results

04/16/20

Auris Medical Provides Update on Intranasal Betahistine Development Program

04/03/20

Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine

03/05/20

Auris Medical Highlights Publication of Study Results Demonstrating Betahistine’s Antiepileptogenic and Anticonvulsant Activity in Murine Model

02/25/20

Auris Medical Announces Notice of Allowance for European Patent Application

01/10/20